<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721991</url>
  </required_header>
  <id_info>
    <org_study_id>H17041847</org_study_id>
    <nct_id>NCT03721991</nct_id>
  </id_info>
  <brief_title>GABA Treatment in Subjects With Type 1 Diabetes</brief_title>
  <acronym>GABA-1</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel Group, Single-centre Trial of GABA Treatment in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      test if a food supplementation with GABA can improve insulin production capacity in type 1
      diabetes patients by turning alfa cells into beta cells in accordance with mice and cell
      studies.randomised parallel study with placebo as control
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      our results indicate that alfa-cells can be regenerated and used to regenerate functional
      beta-like cells in vivo in type 1 diabetes models. Aiming to eventually apply these findings
      to type 1 diabetic patients, we initiated multiple screens seeking for compounds inducing
      alfa-to-beta-cell conversion. Using the mouse as a model, we thereby found that GABA
      (gamma-aminobutyric acid) could promote a cycle of conversion of alfa-cells into functional
      beta-like cells,GABA being considered as a non-harmful food supplement, one could envision a
      trial in type 1 diabetic patients. Indeed, a putative cure for type 1 diabetes may include
      halting the autoimmune insult to the pancreatic beta-cells and restoring insulin secretion by
      expanding beta-cell mass by beta-cell-regeneration and/or preventing beta-cell apoptosis
      induced by cytokines. Immunosuppression initiated at the onset of type 1 diabetes has been
      shown to preserve beta-cell function, but is associated with significant toxicities. Other
      studies using nicotinamide and parenteral insulin have failed to prevent development of type
      1 diabetes.

      Objectives Primary objective: To investigate the effect and safety of the dietary supplement
      GABA provided at a dose of 6 g daily compared to placebo for 12 weeks on change in beta-cell
      function in patients with C-peptide negative type 1 diabetes as an adjunctive therapy to
      insulin treatment.

      Population A total of 30 patients with C-peptide negative type 1 diabetes, randomised 2:1
      GABA: Placebo.

      Intervention After randomisation patients are treated with the dietary supplement GABA or
      matching placebo, titrated to 3 x 2g, or maximum tolerated dose, for 12 weeks. The insulin
      dose is reduced if needed according to Self-monitored blood glucose (SMBG) and hypoglycaemic
      episodes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomised controlled study with active compared to placebo for 12 weeks</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>randomised controlled with placebo tablets matching active capsules with investigational product</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>insulin production</measure>
    <time_frame>12 weeks</time_frame>
    <description>c peptide production during meal stimulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>c peptide response (change from fasting baseline to meal stimulated concentration in blood)</measure>
    <time_frame>after 12 weeks</time_frame>
    <description>maximal c peptide change from baseline during meal testing with sustacal,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>c peptide response beta cell</measure>
    <time_frame>after 12 weeks</time_frame>
    <description>beta cell sensitivity during meal testing, calculated with Homeostatic Model assessment b (HOMAb)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucagon response</measure>
    <time_frame>after 12 weeks</time_frame>
    <description>increase in blood glucagon concentration from fasting to peak during meal testing,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic parameters</measure>
    <time_frame>12 weeks</time_frame>
    <description>hba1c (mmol/mol) change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic parameters dose of insulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>insulin dose used pr 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic parameters glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>hypoglycemia,(number of events of severe and mild hypoglycemia self reported)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic parameters lipid</measure>
    <time_frame>12 weeks</time_frame>
    <description>lipid (LDL cholesterol ) (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic parameters weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>body weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic parameters waist</measure>
    <time_frame>12 weeks</time_frame>
    <description>waist circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic parameters SMBG</measure>
    <time_frame>12 weeks</time_frame>
    <description>SMBG self monitored blood glucose (mmol/l) 7 points profile in diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic parameters quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quality of life questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>GABA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gamma Amino butyric acid (GABA) food supplement with 6 g per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsules to GABA</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gama amino butyric acid (GABA)</intervention_name>
    <description>food supplement Gama amino butyric acid (GABA) as capsules</description>
    <arm_group_label>GABA</arm_group_label>
    <other_name>gaba</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:stimulated c peptide &lt;0.03 mmol/l type 1 diabetes

        -

        Exclusion Criteria:

          -  â€¢ Type 2 diabetes

               -  Fertile women not using chemical (tablet/pill, depot injection of progesterone,
                  subdermal gestagen implantation, hormonal vaginal ring or transdermal hormonal
                  patch) or mechanical (spirals) contraceptives

               -  Pregnant or nursing women

               -  Cancer unless in complete remission for &gt; 5 years

               -  Treatment with oral glucocorticoids

               -  Hypoglycaemia unawareness (unability to register low blood glucose)

               -  Known or suspected hypersensitivity to trial product or related products

               -  Abuse of alcohol or drugs, or any other co-existing condition that would make
                  patients unsuitable to participate in the study, as deemed by the investigators

               -  Receipt of an investigational drug within 30 days prior to visit 0

               -  Simultaneous participation in any other clinical intervention trial

               -  Chronic systemic use of steroids

               -  Seizure disorder

               -  Current use of Baclofen, Valium, Acamprosate, Neurontin, or Lyrica
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>peter Rossing, md</last_name>
    <role>Study Chair</role>
    <affiliation>Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Rossing, MD</last_name>
    <phone>004530913383</phone>
    <email>peter.rossing@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Rossing, MD</last_name>
      <email>peter.rossing@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Peter Rossing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>October 25, 2018</last_update_submitted>
  <last_update_submitted_qc>October 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>beta cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Butyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>data protection rules may not approve data sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

